Skip to content
AnalystLens

DEXCOM INC 8-K Report, Financial Results (Jul 30, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 30, 2026
Period End
July 30, 2026
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’16Jun ’16
  2. Restructuring8-K · Feb ’19Feb ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Sep ’25Sep ’25

01—Abstract

Summary

Summary of the 8-K filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.

DexCom reported second-quarter 2026 revenue of $1.308 billiona, up 13% year-over-year on a reported basis and 12% on an organic basis, with U.S. revenue up 11% and international revenue up 19% (16% organic).

Profitability improved sharply: GAAP operating income rose to $318.3 millionb, or 24.3% of revenue, from $212.6 million (18.4%) a year earlier, and non-GAAP operating margin reached 25.1%. GAAP diluted EPS was $0.64 versus $0.45, and non-GAAP diluted EPS was $0.70 versus $0.48. Gross margin also expanded, with GAAP gross margin at 63.4% and non-GAAP at 64.1%, compared with 59.5% and 60.1% in the prior-year quarter.

Management raised the midpoint of its full-year 2026 revenue guidance to $5.18c–$5.25 billion (roughly 11–13% growth) and raised its non-GAAP gross margin (about 64%), non-GAAP operating margin (about 23.5–24%), and Adjusted EBITDA margin (about 31.5–32%) outlooks. The company also held its 2026 Investor Day and introduced a long-term financial outlook through 2030. Strategic news included positive results from the CONNECT randomized controlled trial in type 2 diabetes patients not using insulin, and the launch of a redesigned Stelo consumer app with AI-driven insights.

Balance sheet activity was mixed. Cash, cash equivalents, and marketable securities totaled about $1.95 billiond, and the revolving credit facility remains undrawn. Treasury stock rose by roughly $643 million during the first half, indicating meaningful share repurchases, and net shares outstanding declined from about 384.8 million to 377.4 million.

Inventory grew about 15% and receivables about 3% since year-end, which investors may want to monitor against revenue growth. This 8-K furnishes the earnings release under Item 2.02 and is not deemed filed under the Exchange Act.

02—Key points

Key Highlights

  1. Revenue rose 13% year-over-year to $1.308 billion (12% organic), with international growth of 19% outpacing U.S. growth of 11%.
  2. GAAP operating margin expanded about 590 basis points to 24.3%, and non-GAAP operating margin reached 25.1%, both up 590 basis points year-over-year.
  3. GAAP diluted EPS was $0.64 (vs. $0.45) and non-GAAP diluted EPS was $0.70 (vs. $0.48); GAAP net income was $249.1 million.
  4. FY2026 guidance was raised: revenue of $5.18–$5.25 billion, non-GAAP gross margin of about 64%, non-GAAP operating margin of 23.5–24%, and Adjusted EBITDA margin of 31.5–32%.
  5. CONNECT RCT showed statistically significant and clinically meaningful glucose control improvements for type 2 patients not using insulin using Dexcom CGM versus routine care; 2026 Investor Day introduced a long-term outlook through 2030.
  6. Cash and marketable securities of $1.95 billion with an undrawn revolver, while treasury stock increased by about $643 million, signaling active share repurchases.
  7. Inventory rose about 15% year-to-date to $726.4 million, which may reflect capacity expansion and should be watched against sales growth.

03—Questions

Frequently Asked Questions

  1. How strong was DexCom's Q2 2026 growth and profitability compared with last year?

    Revenue grew 13% to $1.308 billion (12% organic), and GAAP operating income nearly doubled from $212.6 million to $318.3 million. GAAP operating margin rose from 18.4% to 24.3%, driven by higher gross margin (63.4% vs. 59.5%) and operating leverage on SG&A and R&D, which grew more slowly than revenue.

  2. Did DexCom change its full-year 2026 outlook?

    Yes. The company raised the midpoint of its revenue guidance to $5.18–$5.25 billion (about 11–13% growth) and increased its guidance for non-GAAP gross margin (about 64%), non-GAAP operating margin (23.5–24%), and Adjusted EBITDA margin (31.5–32%). The filing does not state the prior ranges, so the size of the raise cannot be determined from this document.

  3. What does the CONNECT trial mean for DexCom?

    CONNECT is a randomized controlled trial showing that CGM use in people with type 2 diabetes not on insulin produced clinically meaningful and statistically significant glucose control improvements versus routine care. This supports expansion of CGM into a broader, non-insulin patient population, which is a potential long-term demand driver, though the filing does not quantify the commercial impact.

  4. Is DexCom returning capital to shareholders, and what is its liquidity position?

    Treasury stock increased from $2,084.8 million to $2,728.0 million during the first half of 2026, implying roughly $643 million of repurchases, and treasury shares rose from 25.9 million to 35.0 million. Cash, equivalents, and marketable securities total about $1.95 billion, and the $1.25 billion revolving credit facility remains undrawn. Convertible notes carried at about $1.24 billion are the main debt on the balance sheet.

  5. Are there any working capital or quality-of-earnings concerns?

    Inventory increased about 15% to $726.4 million and accounts receivable rose about 3% to $1,257.7 million since December 31, 2025, while revenue grew 13% year-over-year. Inventory build may reflect production capacity expansion, but investors should review the cash flow statement in the 10-Q, which is not included here, to assess operating cash generation relative to reported earnings.

04—Continue

← View all 8-K filings